Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GRAIL, LLC (GRAL)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: GRAL (5-star) is a STRONG-BUY. BUY since 37 days. Simulated Profits (118.26%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $61.5
1 Year Target Price $61.5
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 277.07% | Avg. Invested days 38 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.91B USD | Price to earnings Ratio - | 1Y Target Price 61.5 |
Price to earnings Ratio - | 1Y Target Price 61.5 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 13.58 - 103.00 | Updated Date 11/5/2025 |
52 Weeks Range 13.58 - 103.00 | Updated Date 11/5/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.71 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-11-12 | When After Market | Estimate -3.33 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -368.15% |
Management Effectiveness
Return on Assets (TTM) -11.81% | Return on Equity (TTM) -17.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1792784029 | Price to Sales(TTM) 21.66 |
Enterprise Value 1792784029 | Price to Sales(TTM) 21.66 | ||
Enterprise Value to Revenue 13.35 | Enterprise Value to EBITDA - | Shares Outstanding 36047799 | Shares Floating 31063830 |
Shares Outstanding 36047799 | Shares Floating 31063830 | ||
Percent Insiders 14 | Percent Institutions 68.03 |
Upturn AI SWOT
GRAIL, LLC
Company Overview
History and Background
GRAIL, LLC was founded in 2016 by Illumina. It was created to develop a multi-cancer early detection (MCED) test using next-generation sequencing (NGS). Illumina reacquired GRAIL in 2021.
Core Business Areas
- Early Cancer Detection: Developing and commercializing Galleri, a multi-cancer early detection blood test.
- Genomic Sequencing: Utilizing genomic sequencing technology for cancer screening.
Leadership and Structure
The leadership structure following Illumina's acquisition is integrated within Illumina's management. The company focuses on R&D and commercialization of Galleri.
Top Products and Market Share
Key Offerings
- Galleri: A multi-cancer early detection (MCED) blood test. Market share data is evolving. Competitors include Exact Sciences (EXAS) with their cancer diagnostic offerings, and various research institutions working on liquid biopsy technologies.
Market Dynamics
Industry Overview
The industry is focused on early cancer detection using liquid biopsy technology. It is a rapidly evolving field with significant investment and research activity.
Positioning
GRAIL is positioned as a leader in the MCED space with its Galleri test. Competitive advantages include its extensive dataset and NGS technology.
Total Addressable Market (TAM)
The TAM for MCED tests is estimated to be in the tens of billions of dollars annually. GRAIL aims to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Proprietary technology
- Large dataset
- Early mover advantage
- Backed by Illumina's resources
- Clinically validated test
Weaknesses
- High cost of the test
- Limited reimbursement coverage
- Need for further clinical validation
- Regulatory uncertainty
- Ethical considerations
Opportunities
- Expansion of reimbursement coverage
- Development of new cancer detection tests
- Partnerships with healthcare providers
- International expansion
- Integration with electronic health records
Threats
- Competition from other MCED test developers
- Regulatory hurdles
- Negative clinical trial results
- Changes in healthcare policy
- Ethical and societal concerns
Competitors and Market Share
Key Competitors
- EXAS
Competitive Landscape
GRAIL has a strong position in the MCED market due to its innovative technology, but faces competition from established players like Exact Sciences with their existing diagnostic platforms. GRAIL's partnership with Illumina provides significant resources, but regulatory challenges and reimbursement hurdles remain.
Growth Trajectory and Initiatives
Historical Growth: GRAIL's growth is tied to the adoption rate of Galleri and the expansion of its clinical utility.
Future Projections: Future growth is dependent on regulatory approvals, reimbursement coverage, and clinical adoption of Galleri. Analyst estimates for Illumina reflect these factors.
Recent Initiatives: Recent initiatives include expanding clinical validation studies for Galleri and pursuing regulatory approvals.
Summary
GRAIL, now under Illumina, is focused on its multi-cancer early detection test, Galleri. Its strengths lie in its technology and Illumina's backing. The company faces challenges in reimbursement, regulatory approvals, and competition. Future success hinges on expanding clinical validation and market adoption of Galleri.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Illumina Investor Relations
- Analyst Reports
- Company Press Releases
- Academic Publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Financial data related to GRAIL is embedded in Illumina's consolidated reporting.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GRAIL, LLC
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2024-06-25 | CEO & Director Mr. Robert P. Ragusa | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1000 | Website https://grail.com |
Full time employees 1000 | Website https://grail.com | ||
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.